Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Assist Reprod Genet ; 38(11): 2915-2923, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1530351

ABSTRACT

OBJECTIVE: To determine whether euploidy rates and blastocyst development differ in a continuous culture medium under different CO2 concentrations. DESIGN AND METHOD: A single-center retrospective study was performed from July 2018 to October 2019 including 44 fresh cycles with at least four fresh mature oocytes (MII) without severe male factor infertility. Sibling MII were injected and cultured in Global®Total®LP under 6.0% (pHe = 7.374 ± 0.014) or 7.0% (pHe = 7.300 ± 0.013) CO2, 5.0% O2, and 89.0% or 88.0% N2. Analyzed variables were normally fertilized oocytes (2PN), cleavage rate, blastulation rate on day 5/2PN, usable blastocyst (blastocysts biopsied/2PN), and euploidy rates. Blastocyst's trophectoderm biopsy was performed on day 5, 6, or 7 for genetic testing and mitochondrial DNA (mtDNA) quantification by next-generation sequencing. RESULTS: Women's mean age was 33.0 ± 6.6 years old. From a total of 604 MII, no differences were found in normal fertilization and cleavage rates on day 3 between 6.0 and 7.0% CO2 (72.3% vs 67.1%, p = 0.169 and 96.6% vs 96.3%, p = 0.897, respectively). Blastulation rate on day 5/2PN was comparable between 6.0 and 7.0% CO2 (68.1% vs 64.2%, p = 0.409). Although usable blastocyst rate was not different (54.3% vs 55.3%, p = 0.922), total euploidy rates differed significantly (58.7% vs 42.8%, p = 0.016) between 6.0% and 7.0% CO2, respectively. The mean blastocyst mtDNA content was significantly lower in 6.0% CO2 (30.4 ± 9.1 vs 32.9 ± 10.3, p = 0.037). CONCLUSION: Blastocyst development is not affected when embryos are cultured in vitro at 6.0% or 7.0% CO2, while euploidy rates are significantly decreased at a higher CO2 concentration, therefore at a lower pHe.


Subject(s)
Blastocyst/cytology , Carbon Dioxide/pharmacology , Chromosome Aberrations/drug effects , Embryo Culture Techniques/methods , Fertilization in Vitro/methods , Oocytes/cytology , Adult , Blastocyst/drug effects , Embryo Implantation , Embryo Transfer , Female , Genetic Testing , Humans , Hydrogen-Ion Concentration , Male , Oocytes/drug effects , Pregnancy , Preimplantation Diagnosis/methods , Retrospective Studies , Siblings
2.
J Assist Reprod Genet ; 37(10): 2393-2398, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-692491

ABSTRACT

Examine good tissue practices as relates to in vitro fertilization, biopsying, and vitrificationto compare current knowledge of ova, sperm, and embryos as vectors for disease transmission as it relates to our current knowledge regarding the SARS-CoV-2 virus.Unknown risks relating to the SARS-CoV-2 virus and sperm, ova, and embryos necessitate a reexamining of how human IVF is performed. Over the last decade, improvements in cryosurvival and live birth outcomes have been associated with zona pellucida breaching procedures (e.g., blastocyst collapsing and biopsying). In turn, today embryos are generally no longer protected by an intact zona pellucida when vitrified and in cryostorage. Additionally, high security storage containers have proven to be resilient to potential cross-contamination and reliable for routine human sperm freezing and embryo vitrification.Several options to current IVF practices are presented that can effectively mitigate the risks of cross-contamination and infection due to the current Covid-19 pandemic or other viral exposures. The question remains; is heightened security and change warranted where the risks of disease transmission likely remain negligible?


Subject(s)
Coronavirus Infections/virology , Fertilization in Vitro , Oocytes/growth & development , Pandemics , Pneumonia, Viral/virology , Betacoronavirus/pathogenicity , Blastocyst/virology , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Cryopreservation , Embryo Culture Techniques/methods , Embryo Transfer/methods , Embryo, Mammalian/virology , Female , Humans , Live Birth/epidemiology , Oocytes/virology , Pneumonia, Viral/complications , Pneumonia, Viral/epidemiology , Pregnancy , Pregnancy Complications, Infectious/virology , Pregnancy Rate , SARS-CoV-2 , Vitrification , Zona Pellucida
SELECTION OF CITATIONS
SEARCH DETAIL